NATCAPSUQ
Natural Capsules Limited
NSELast Traded Price
₹209.3
-4.86 (-2.27%)
Open
₹215.24
High
₹219.7
Low
₹203.5
Prev Close
₹214.16
Industry
Pharmaceuticals
Market Cap
217.91 Cr
Filing History
Recent corporate announcements and filings for NATCAPSUQ
Governance
Neutral
2026-08-18 15:43
- Intimation of Record Date for Extraordinary General Meeting (EGM).
- EGM Date: September 9th, 2026.
- Record Date: September 2nd, 2026.
Governance
Positive
2026-08-18 15:38
- Natural Capsules Limited to hold an Extraordinary General Meeting (EGM) on September 09, 2026, at 12:00 PM (IST) via Video Conference.- The EGM agenda includes preferential allotment of 1,25,000 equity shares (₹2 Cr) and up to 5,00,000 warrants (₹8 Cr) to Promoter Mr. Sunil Laxminarayan Mundra, both at ₹160 per share/warrant.
Governance
Negative
2026-08-17 18:59
CRITICAL RED FLAG DETECTED
- Mr. Pramod Kasat resigned as an Independent Director of Natural Biogenex Private Limited, a Material Unlisted Subsidiary, effective August 17, 2026. The resignation is attributed to professional commitments.
Financials
Positive
2026-08-13 01:18
- Q1 FY27 Consolidated Revenue ₹48.71 Cr vs ₹45.20 Cr (▲8% YoY)
- EBITDA ₹1.12 Cr vs ₹0.32 Cr (▲251% YoY)
- PAT (₹5.74 Cr) vs (₹5.58 Cr) (▲3% YoY)
- EBITDA Margin 2.30% vs 0.71% (▲159bps)
Financials
Positive
2026-08-13 01:12
- Q1 FY27 Consolidated Revenue ₹48.71Cr vs ₹58.69Cr (▼17% YoY)
- EBITDA ₹1.12Cr vs ₹0.32Cr (▲251% YoY)
- PAT ₹(5.74)Cr vs ₹(5.92)Cr (▲3% YoY)
- EBITDA Margin 2.30% vs 0.71% (▲159bps)
Governance
Positive
2026-08-12 19:56
- Natural Biogenex Private Limited (material unlisted subsidiary) appointed Mr. K. H. Honneshaiah as its new Chief Operating Officer on August 12, 2026.
- He has 36 years of experience in operations and manufacturing leadership, with a track record of driving profitable growth.
Financials
Positive
2026-08-12 18:18
- Q1 FY27 Consolidated Revenue ₹48.71 Cr vs ₹45.20 Cr (▲7.76% YoY)
- EBITDA ₹3.47 Cr vs ₹0.68 Cr (▲412.01% YoY)
- PAT -₹5.74 Cr vs -₹5.58 Cr (Loss increased by 2.92% YoY)
- EBITDA Margin 7.13% vs 1.50% (▲563 bps)
- Approved a Preferential Issue of 1,25,000 Equity Shares and 5,00,000 Convertible Warrants to the promoter/promoter group at ₹160 each, aggregating to ₹10 Cr.
- Approved the draft Notice for an Extra Ordinary General Meeting (EGM) to be held on September 9, 2026.
- Appointed M/S Deepak Sadhu as Scrutinizer for the E-voting Process.
Governance
Neutral
2026-08-12 18:14
- Board of Directors approved Unaudited Consolidated & Standalone Financial Results for Quarter ended June 30, 2026.
- Approved a preferential issue of 1,25,000 equity shares and 5,00,000 convertible warrants to promoter/promoter group at ₹160 each.
- Approved draft Notice of Extra Ordinary General Meeting on September 9, 2026.
- Appointed M/S Deepak Sadhu as Scrutinizer for E-voting.
Ownership
Positive
2026-07-31 17:54
- Natural Biogenex Private Limited, a material unlisted subsidiary, approved the allotment of a Rights Issue.
- 9,46,305 Equity Shares of face value ₹10/- each, aggregating to ₹94,63,050/-, were allotted for cash at par.
Routine
Neutral
2026-07-29 19:09
New Filing detected. See link for details.
Governance
Neutral
2026-07-17 18:09
- The 33rd Annual General Meeting (AGM) of Natural Capsules Limited is scheduled for August 12, 2026, at 12:00 PM (IST) via Video Conference (VC) or OAVM.
- The agenda includes adoption of financial statements, re-appointment of directors, revision of Whole-time Director's remuneration, and approval of Related Party Transactions up to ₹50 Cr with Natural Biogenex Private Limited.
- Remote e-voting will be available from August 08, 2026 (09:00 AM) to August 11, 2026 (05:00 PM), with August 05, 2026, as the record date.
Governance
Neutral
2026-07-17 13:57
- Intimation of Record Date for the 33rd Annual General Meeting (AGM).
- AGM Date: August 12, 2026.
- Record Date for AGM: August 05, 2026.
Routine
Neutral
2026-07-10 17:50
New Filing detected. See link for details.
Routine
Neutral
2026-07-10 17:37
New Filing detected. See link for details.
Routine
Neutral
2026-06-25 13:17
- The Trading Window for dealing in the Company's equity shares will remain closed from July 01, 2026.
- It will reopen 48 hours after the declaration of financial results for the quarter ended June 30, 2026.
- The Board Meeting date for declaring results will be intimated later.